Fabry Disease Market (By Treatment, Route of Administration, End User, Country), Key Company Profiles, Product Analysis and Market Dynamics – Forecast to 2030

The global Fabry disease treatment market was valued at USD 2,215 Million in 2024, and is projected to reach USD 3,856 Million by 2030. Fabry disease is a rare genetic disorder resulting from a deficiency or malfunction of the enzyme called alpha-galactosidase A (α-GAL A). This enzyme is crucial for breaking down a type of fat called globotriaosylceramide (GL-3 or Gb3) in the body's cells. Without enough functional α-GAL A, this fat builds up, especially in blood vessels, kidneys, heart, and nerves, leading to progressive damage. The main objective of Fabry disease treatment is to minimize the buildup of globotriaosylceramide (Gb3) in the body, relieve associated symptoms, slow or prevent the progression of organ damage, and enhance patients’ overall quality of life. The increasing number of patients suffering from Fabry disease and the escalating need for precise and effective therapies, such as enzyme replacement substrate reduction, chaperone treatments, and substrate reduction therapy to stabilize individuals from suffering disease, are growth-inducing factors for the market.

Key Highlights of the Report

According to estimates published by Fabry Institute, 1 in 20,000 females and 1 in 40,000 males are thought to be affected by Fabry disease.

The innovations in enzyme replacement therapy (ERT), chaperone therapy, and substrate reduction therapy (SRT) are enhancing treatment efficacy and patient outcomes.

The recent approvals, such as Amicus Therapeutics' Galafold and Protalix BioTherapeutics' Elfabrio, are providing patients with more treatment options.

Galafold (migalastat) by Amicus Therapeutics is the first oral chaperone therapy approved for adult patients with specific GLA gene mutations.

The intravenous route dominates the Fabry disease market owing to its high efficacy in delivering enzyme replacement therapy (ERT) for Fabry disease.

Oral route offers a convenient way of administering treatments, which is particularly advantageous for patients who require long-term therapy.

Fabrazyme continues to hold a substantial share of the global Fabry disease market, supported by strong regulatory approvals, broad geographic availability, and widespread clinical acceptance.

Replagal gained widespread adoption in Europe and Asia, where it became a mainstay therapy in managing Fabry disease, particularly in patients seeking long-term enzyme replacement with a well-established safety profile.

Hospitals segment is anticipated to dominate the Fabry disease treatment market, largely because of the high level of expertise involved in treating this rare genetic disorder.

Online pharmacies provide convenient access to medication, such as oral therapy, including chaperone therapy, which can be administered at home, lowering hospital visit requirements.

The United States dominates the Fabry disease market owing to increasing disease awareness, ongoing innovation and the introduction of novel treatments, and a robust healthcare infrastructure.

Germany stands as the leading market for Fabry disease treatments in Europe, both in terms of revenue and growth potential. Germany's commitment to research is evident through institutions like the German Center for Rare Diseases (DZNE), which actively participates in Fabry disease studies and clinical trials.

Apelo Consulting report titled “Fabry Disease Market (By Treatment, Route of Administration, End User, Country), Key Company Profiles, Product Analysis and Market Dynamics – Forecast to 2030” provides a complete assessment of the fast–evolving Fabry Disease Market landscape.


This 110 Pages report with 60 Figures and 10 Tables has been analyzed from 9 pointers:

1) Global - Fabry Disease Market and Forecast (2021 – 2030)

2) Global - Fabry Disease Market Share and Forecast (2021 – 2030)

3) By Treatment – Global Fabry Disease Market and Forecast (2021 – 2030)

4) By Route of Administration – Global Fabry Disease Market and Forecast (2021 – 2030)

5) By Product – Global Fabry Disease Market and Forecast (2021 – 2030)

6) By End User – Global Fabry Disease Market and Forecast (2021 – 2030)

7) By Country – Fabry Disease Market and Forecast (2021 – 2030)

8) Global Fabry Disease Market – Company Profiles

9) Global Fabry Disease Treatment – Market Dynamics

Global Fabry Disease Market and Forecast - By Treatment

1. Enzyme Replacement Therapy

2. Chaperone Treatment

3. Substrate Reduction Therapy

4. Others

Global Fabry Disease Market and Forecast - By Product

1. Fabrazyme (Agalsidase beta)

2. Elfabrio (Pegunigalsidase alfa)

3. Replagal

4. Galafold (Migalastat)

Global Fabry Disease Market and Forecast - By End User

Hospitals

Retail Pharmacy

Online Pharmacy

Global Fabry Disease Market and Forecast - By Country

United States

Canada

Mexico

Germany

France

UK

Italy

Spain

Japan

China

Australia

Saudi Arabia

UAE

South Africa

Brazil

Argentina

Global Fabry Disease Market – Company Profiles

1. Sanofi

2. Protalix Biotherapeutics

3. Amicus Therapeutics

4. Takeda Pharmaceutical

5. uniQure

6. AceLink Therapeutics

7. Sangamo Therapeutics

8. 4D Molecular Therapeutics

9. Greenovation Biopharmaceuticals

10. Idorsia

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.

Show more